In 1991, research nurse Karen Rapp was hired by the UC San Diego Stroke Center to oversee a new clinical trial. The goal: to ...

A team of scientists from the University of Colorado, Boulder just published an article, "The non-nutritive sweetener erythritol adversely affects brain microvascular endothelial cell function," in ...

Therapies that boost brain plasticity and repair processes without deleterious side effects have the potential to transform the clinical management of stroke. Here we report that tissue plasminogen ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ...

Tenecteplase (TNK) is a thrombolytic tissue plasminogen activator (tPA) drug that can break down blood clots after an ischemic stroke. It is available as a single dose with a half-life of 20 to 25 ...

Chiesi Farmaceutici has filed a patent for stable formulations of tissue-type plasminogen activator (tPA). The patent claims a liquid composition containing specific amounts of tPA, tranexamic acid, ...

Plasminogen concentration, plasminogen activity, high-sensitivity C-reactive protein (hs-CRP), 2-antiplasmin, plasminogen activator inhibitor 1, and tissue plasminogen activator antigen were all ...

Tissue plasminogen activator (tPA) is a medication that doctors administer following a stroke caused by a blood clot. It breaks up the blood clot to allow blood flow to return to the brain.

Emergency treatment with a blood clot buster called tissue plasminogen activator for a patient who had a stroke while being treated with the experimental Alzheimer's drug lecanemab led to a fatal ...